The Health Care Select Sector SPDR Fund is a passively managed exchange-traded fund that seeks to match, before fees and expenses, the price and yield performance of the Health Care Select Sector Index. That benchmark includes the health care constituents of the S&P 500, spanning pharmaceuticals, biotechnology, health care equipment and supplies, health care providers and services, and life sciences tools and services. The fund employs a replication strategy, generally investing substantially all of its assets in the underlying index securities.
XLV holds approximately 60 to 64 positions, with assets under management in the low-to-mid $40 billion range, making it one of the largest health care sector ETFs. Its expense ratio is 0.08%, among the lowest in the category. The portfolio is top-heavy: Eli Lilly is the largest holding at roughly 15% of assets, followed by Johnson & Johnson near 10% and AbbVie around 7% to 8%. Other sizable positions include Merck, UnitedHealth Group, Thermo Fisher Scientific, Amgen, Gilead Sciences, and Abbott Laboratories. This concentration means a sharp move in any single mega-cap name can meaningfully sway overall fund returns. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
The broader health care environment reflects a mix of defensive characteristics and structural growth drivers. Demand for medical services, pharmaceuticals, and devices tends to remain relatively stable across economic cycles, which can make the sector attractive during periods of macroeconomic uncertainty. At the same time, innovation in areas such as GLP-1 obesity and diabetes therapies, immunology, oncology, and surgical robotics has supported earnings growth and investor interest in several of the sector's largest companies.
Monetary policy and interest rates also influence the sector. Health care equities, particularly large, cash-generative pharmaceutical and managed-care names, are often viewed as defensive relative to more cyclically sensitive industries. Inflation, drug-pricing legislation, and evolving regulatory frameworks in the United States remain important watchpoints, while capital flows into and out of sector ETFs reflect shifting investor sentiment on growth versus value positioning.
In recent weeks, XLV showed a pattern of gradual weakness followed by a sharp recovery. After trading in the low $170s in late August, the fund pulled back toward the mid-$160s in late September and early October before rallying back above $179 by late October. Over the most recent 30-day period, this translated to an advance of roughly 6%, a move that remained range-bound rather than volatile in nature.
The rebound was led disproportionately by the portfolio's largest pharmaceutical positions. Eli Lilly has posted a strong multi-month advance tied to continued momentum in its obesity and diabetes franchise, while Merck and Johnson & Johnson have also contributed meaningfully. With the top ten holdings accounting for well over half of the fund's assets, concentration has amplified the influence of these names on sector-level performance. Broader sector rotation toward defensives and health care innovation themes reinforced the move. From what I see, this concentration is worth monitoring closely.
Several structural factors are likely to shape XLV during 2026. The earnings cycles of its largest pharmaceutical and biotech holdings will remain central, particularly continued demand for GLP-1 therapies and the commercial progress of immunology and oncology pipelines. Interest-rate expectations and the broader inflation backdrop will influence the relative appeal of defensive health care equities against other sectors, while any changes to U.S. drug-pricing or health care policy could alter the profit outlook for managed-care and pharmaceutical companies.
Capital flows into health care ETFs, merger-and-acquisition activity, and the pace of biotech innovation represent additional variables. Because the fund is concentrated in a limited number of mega-cap names, company-specific developments and regulatory decisions may carry outsized influence. Monitoring sector rotation, portfolio holdings, and the macroeconomic environment will be essential for investors assessing how the fund's positioning evolves over the coming months.
In my own research process, I often turn to Tickeron’s AI-powered platforms to cross-check sector trends and identify comparable opportunities. The AI Screener stands out for its ability to scan thousands of securities with technical indicators, fundamentals, volatility measures, AI-generated signals, market trends, price patterns, and customizable filters. It surfaces trending securities and breakout candidates efficiently, helping compare health care exposure against other sectors without replacing independent judgment. This approach adds a structured layer to evaluating funds like XLV alongside broader market dynamics.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where XLV declined for three days, in 250 of 308 cases, the price declined further within the following month. The odds of a continued downward trend are 81%.
The 10-day RSI Indicator for XLV moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 37 similar instances where the indicator moved out of overbought territory. In 27 of the 37 cases, the stock moved lower in the following days. This puts the odds of a move lower at 73%.
The Momentum Indicator moved below the 0 level on November 18, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on XLV as a result. In 72 of 99 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 73%.
The Moving Average Convergence Divergence Histogram (MACD) for XLV turned negative on November 16, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In 38 of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at 78%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
The 10-day moving average for XLV crossed bullishly above the 50-day moving average on October 15, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 77%.
Following a +0.33% 3-day Advance, the price is estimated to grow further. Considering data from situations where XLV advanced for three days, in 264 of 325 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
XLV may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 225 of 273 cases where XLV Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 82%.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows